Nanosonics Files Second US FDA Application as CORIS Rollout Expands
MT Newswires Live
May 26
Nanosonics (ASX:NAN) advanced the staged rollout of its CORIS system by submitting a second application to the US food and drug administration aimed at broadening approved endoscope indications following its earlier clearance, according to a Tuesday filing with the Australian bourse
The company is also progressing its controlled market release (CMR) program, having installed its first CORIS unit in Australia and started staff training in preparation for a planned rollout, per the filing.
The United Kingdom CMR is ongoing and performing as expected, with Australia and Ireland sites rolling out next and US activities to follow based on early learnings, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.